Biotechnology cancer Cancer Discovery Cell Therapy drug development

Anti-Malaria Drugs Have Shown Promise in Treating Cancer, and Now Researchers Know Why

Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson Cancer Center of the University of Pennsylvania say they have identified that target – an enzyme called PPT1 – opening up a new pathway for potential cancer treatments. The team also used CRISPR/Cas9 gene editing
Biotechnology Clinical Trials Pharmaceuticals

A Change in Bacteria’s Genetic Code Holds Promise of Longer-Lasting Drugs

By altering the genetic code in bacteria, researchers at The University of Texas at Austin have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs' effectiveness and convenience, leading to smaller and less frequent doses of medicine, lower health care costs and fewer side effects for patients with cancer and other diseases. The results were published today in the journal Nature Biotechnology. [June 4, 2018]
Biotechnology cancer Clinical Trials Prodrug

Moffitt Researchers Discover New Targets for Approved Cancer Drug

New study shows ALK inhibitor ceritinib may have the ability to be used for more than ALK-rearranged non-small cell lung cancer Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently. A team of researchers at Moffitt Cancer Center used
Biotechnology Immunotherapies Pharmaceuticals

Drug targeting technique could aid therapies for immune diseases

A new technique that targets drugs to specific cells could lead to improved therapies for diseases caused by an overactive immune response. The approach could help people affected by conditions such as arthritis and inflammatory bowel diseases, where the body's own immune system mistakenly attacks healthy tissues. Researchers focused on a group of immune cells called macrophages - some of which help the body heal after injury, while others can
Biotechnology cancer Prodrug

Inhibitor drug improves overall survival in older radioiodine resistant thyroid cancer

The drug lenvatinib can significantly improve overall survival rates in a group of thyroid cancer patients whose disease is resistant to standard radioiodine treatment, according to new research from the Perelman School of Medicine at the University of Pennsylvania. The study, published today in the Journal of Clinical Oncology, is the first to show lenvatinib has a definitive impact on overall survival (OS). Researchers found OS improves in patients older
cancer Prodrug

Drug Developed at University of Minnesota Increases Survival in Dogs with Cancer

A breakthrough trial at the University of Minnesota testing a new UMN-developed drug resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA). The results were published today in the journal Molecular Cancer Therapeutics. “This is likely the most significant advance in the treatment of canine HSA in the last three decades,” said study co-author Jaime Modiano, V.M.D., Ph.D. professor in the University of Minnesota College
Alzheimers and Dementia Biotechnology Prescriptions

Eli Lilly, Biogen, and Neurotrope Fight to Find Viable Treatment for Alzheimer’s Disease

Repeated attempts to treat or even slow the relentless progression of Alzheimer's disease by targeting just one red flag in patient's brains have continued to lead to disappointing outcomes. Last Sunday "Sixty Minutes" episode aired on Columbian extended families that inherited a genetic defect that causes early onset Alzheimer's, by the time they reach 45 years old. Watching the episode brings to light another case in which a young lady